Literature DB >> 27208341

Prognostic Classification Factors Associated With Development of Multiple Autoantibodies, Dysglycemia, and Type 1 Diabetes-A Recursive Partitioning Analysis.

Ping Xu1, Jeffrey P Krischer2.   

Abstract

OBJECTIVE: To define prognostic classification factors associated with the progression from single to multiple autoantibodies, multiple autoantibodies to dysglycemia, and dysglycemia to type 1 diabetes onset in relatives of individuals with type 1 diabetes. RESEARCH DESIGN AND METHODS: Three distinct cohorts of subjects from the Type 1 Diabetes TrialNet Pathway to Prevention Study were investigated separately. A recursive partitioning analysis (RPA) was used to determine the risk classes. Clinical characteristics, including genotype, antibody titers, and metabolic markers were analyzed.
RESULTS: Age and GAD65 autoantibody (GAD65Ab) titers defined three risk classes for progression from single to multiple autoantibodies. The 5-year risk was 11% for those subjects >16 years of age with low GAD65Ab titers, 29% for those ≤16 years of age with low GAD65Ab titers, and 45% for those subjects with high GAD65Ab titers regardless of age. Progression to dysglycemia was associated with islet antigen 2 Ab titers, and 2-h glucose and fasting C-peptide levels. The 5-year risk is 28%, 39%, and 51% for respective risk classes defined by the three predictors. Progression to type 1 diabetes was associated with the number of positive autoantibodies, peak C-peptide level, HbA1c level, and age. Four risk classes defined by RPA had a 5-year risk of 9%, 33%, 62%, and 80%, respectively.
CONCLUSIONS: The use of RPA offered a new classification approach that could predict the timing of transitions from one preclinical stage to the next in the development of type 1 diabetes. Using these RPA classes, new prevention techniques can be tailored based on the individual prognostic risk characteristics at different preclinical stages.
© 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27208341      PMCID: PMC4878220          DOI: 10.2337/dc15-2292

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  25 in total

1.  The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study.

Authors:  Jeffrey P Krischer; Kristian F Lynch; Desmond A Schatz; Jorma Ilonen; Åke Lernmark; William A Hagopian; Marian J Rewers; Jin-Xiong She; Olli G Simell; Jorma Toppari; Anette-G Ziegler; Beena Akolkar; Ezio Bonifacio
Journal:  Diabetologia       Date:  2015-02-10       Impact factor: 10.122

2.  Diagnosis and classification of diabetes mellitus.

Authors: 
Journal:  Diabetes Care       Date:  2014-01       Impact factor: 19.112

3.  The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results.

Authors:  Jeffrey L Mahon; Jay M Sosenko; Lisa Rafkin-Mervis; Heidi Krause-Steinrauf; John M Lachin; Clinton Thompson; Polly J Bingley; Ezio Bonifacio; Jerry P Palmer; George S Eisenbarth; Joseph Wolfsdorf; Jay S Skyler
Journal:  Pediatr Diabetes       Date:  2008-09-24       Impact factor: 4.866

4.  Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk.

Authors:  V Parikka; K Näntö-Salonen; M Saarinen; T Simell; J Ilonen; H Hyöty; R Veijola; M Knip; O Simell
Journal:  Diabetologia       Date:  2012-03-23       Impact factor: 10.122

5.  Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia.

Authors:  Ezio Bonifacio; Liping Yu; Alastair K Williams; George S Eisenbarth; Polly J Bingley; Santica M Marcovina; Kerstin Adler; Anette G Ziegler; Patricia W Mueller; Desmond A Schatz; Jeffrey P Krischer; Michael W Steffes; Beena Akolkar
Journal:  J Clin Endocrinol Metab       Date:  2010-05-05       Impact factor: 5.958

Review 6.  Type 1 diabetes: new perspectives on disease pathogenesis and treatment.

Authors:  M A Atkinson; G S Eisenbarth
Journal:  Lancet       Date:  2001-07-21       Impact factor: 79.321

7.  Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics.

Authors:  Peter Achenbach; Katharina Warncke; Jürgen Reiter; Heike E Naserke; Alistair J K Williams; Polly J Bingley; Ezio Bonifacio; Anette-G Ziegler
Journal:  Diabetes       Date:  2004-02       Impact factor: 9.461

8.  Prognostic accuracy of immunologic and metabolic markers for type 1 diabetes in a high-risk population: receiver operating characteristic analysis.

Authors:  Ping Xu; Craig A Beam; David Cuthbertson; Jay M Sosenko; Jay S Skyler; Jeffrey P Krischer
Journal:  Diabetes Care       Date:  2012-07-11       Impact factor: 19.112

9.  A longitudinal study of GAD65 and ICA512 autoantibodies during the progression to type 1 diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) participants.

Authors:  Jay M Sosenko; Jay S Skyler; Jerry P Palmer; Jeffrey P Krischer; David Cuthbertson; Liping Yu; Desmond A Schatz; Tihamer Orban; George Eisenbarth
Journal:  Diabetes Care       Date:  2011-09-12       Impact factor: 19.112

10.  Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1.

Authors:  Tihamer Orban; Jay M Sosenko; David Cuthbertson; Jeffrey P Krischer; Jay S Skyler; Richard Jackson; Liping Yu; Jerry P Palmer; Desmond Schatz; George Eisenbarth
Journal:  Diabetes Care       Date:  2009-09-09       Impact factor: 17.152

View more
  18 in total

1.  Impact of Age and Antibody Type on Progression From Single to Multiple Autoantibodies in Type 1 Diabetes Relatives.

Authors:  Emanuele Bosi; David C Boulware; Dorothy J Becker; Jane H Buckner; Susan Geyer; Peter A Gottlieb; Courtney Henderson; Amanda Kinderman; Jay M Sosenko; Andrea K Steck; Polly J Bingley
Journal:  J Clin Endocrinol Metab       Date:  2017-08-01       Impact factor: 5.958

2.  Excess BMI Accelerates Islet Autoimmunity in Older Children and Adolescents.

Authors:  Christine Ferrara-Cook; Susan Michelle Geyer; Carmella Evans-Molina; Ingrid M Libman; Dorothy J Becker; Stephen E Gitelman; Maria Jose Redondo
Journal:  Diabetes Care       Date:  2020-01-14       Impact factor: 19.112

3.  The Role of Age and Excess Body Mass Index in Progression to Type 1 Diabetes in At-Risk Adults.

Authors:  Christine T Ferrara; Susan M Geyer; Carmella Evans-Molina; Ingrid M Libman; Dorothy J Becker; John M Wentworth; Antoinette Moran; Stephen E Gitelman; Maria J Redondo
Journal:  J Clin Endocrinol Metab       Date:  2017-12-01       Impact factor: 5.958

Review 4.  Consortium-based approach to receiving an EMA qualification opinion on the use of islet autoantibodies as enrichment biomarkers in type 1 diabetes clinical studies.

Authors:  Stephen R Karpen; Jessica L Dunne; Brigitte I Frohnert; Marjana Marinac; Claudia Richard; Sarah E David; Inish M O'Doherty
Journal:  Diabetologia       Date:  2022-07-22       Impact factor: 10.460

5.  Predicting progression to diabetes in islet autoantibody positive children.

Authors:  Andrea K Steck; Fran Dong; Brigitte I Frohnert; Kathleen Waugh; Michelle Hoffman; Jill M Norris; Marian J Rewers
Journal:  J Autoimmun       Date:  2018-02-01       Impact factor: 7.094

6.  Type 1 Diabetes TrialNet: A Multifaceted Approach to Bringing Disease-Modifying Therapy to Clinical Use in Type 1 Diabetes.

Authors:  Polly J Bingley; Diane K Wherrett; Ann Shultz; Lisa E Rafkin; Mark A Atkinson; Carla J Greenbaum
Journal:  Diabetes Care       Date:  2018-04       Impact factor: 19.112

7.  Transcription Factor 7-Like 2 (TCF7L2) Gene Polymorphism and Progression From Single to Multiple Autoantibody Positivity in Individuals at Risk for Type 1 Diabetes.

Authors:  Maria J Redondo; Andrea K Steck; Jay Sosenko; Mark Anderson; Peter Antinozzi; Aaron Michels; John M Wentworth; Mark A Atkinson; Alberto Pugliese; Susan Geyer
Journal:  Diabetes Care       Date:  2018-10-01       Impact factor: 19.112

8.  Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience.

Authors:  Carla J Greenbaum; Cate Speake; Jeffrey Krischer; Jane Buckner; Peter A Gottlieb; Desmond A Schatz; Kevan C Herold; Mark A Atkinson
Journal:  Diabetes       Date:  2018-05-16       Impact factor: 9.461

9.  Ethnic differences in progression of islet autoimmunity and type 1 diabetes in relatives at risk.

Authors:  Mustafa Tosur; Susan M Geyer; Henry Rodriguez; Ingrid Libman; David A Baidal; Maria J Redondo
Journal:  Diabetologia       Date:  2018-06-21       Impact factor: 10.122

10.  Characteristics of children diagnosed with type 1 diabetes before vs after 6 years of age in the TEDDY cohort study.

Authors:  Jeffrey P Krischer; Xiang Liu; Åke Lernmark; William A Hagopian; Marian J Rewers; Jin-Xiong She; Jorma Toppari; Anette-G Ziegler; Beena Akolkar
Journal:  Diabetologia       Date:  2021-07-22       Impact factor: 10.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.